Skip to main content

Military Health System

Letter to the Editor: G6PD Deficiency in the Tafenoquine Era

Image of A funestus_James Gathany. A funestus_James Gathany

Recommended Content:

Medical Surveillance Monthly Report

In the Dec. 2019 issue of the MSMR, Lee and Poitras reported a 2.2% prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency among active duty U.S. service members between 2004 and 2018.1 Their study utilized Health Level 7-formatted chemistry data archived in the Composite Health Care System (CHCS), but it did not stratify by quantitative or qualitative testing.

When tafenoquine was approved by the U.S. Food and Drug Administration in 2018 for chemoprophylaxis and radical cure of Plasmodium vivax,2 the distinction between quantitative and qualitative testing became clinically significant. Formerly, primaquine was the only approved medication to treat hypnozoites, the dormant form of the parasite in the liver stage of malaria. Its use required a “normal” G6PD activity level, the threshold of which on qualitative tests was usually established at 30%–40%. Tafenoquine, with its longer half-life of 14 days (compared to 6 hours for primaquine), provides a far simpler dosing regimen for malaria chemoprophylaxis and radical cure, but it may precipitate hemolytic anemia at higher levels of G6PD activity. Consequently, the U.S. Centers for Disease Control and Prevention recommends a quantitative G6PD assessment before tafenoquine prescription2 to ensure activity exceeding 70%.3,4

An X-linked genetic disorder, G6PD deficiency in males is usually severe (enzyme activity < 30%), meaning that a “deficient” result on qualitative testing contraindicates the use of both primaquine and tafenoquine. The same is true for females who are homozygous or double heterozygous for mutant alleles—both of which are rare. However, single heterozygous females usually have milder deficiency (enzyme activity 30%–80%),3 meaning they would have a “normal” result on qualitative testing and could safely take primaquine but potentially not tafenoquine.

Univeral G6PD deficiency screening is required across the U.S. Armed Forces, but current policy does not mandate quantitative testing.5 Since tafenoquine may improve medication adherence and thus become a preferable antimalarial option, it is important to understand how many service members have only been qualitatively tested. In the U.S. Air Force, 167,945 active duty members had at least 1 G6PD test performed and recorded in the CHCS between 1 Jan. 2015 and 31 Dec. 2019. Of these, only 4,325 (2.6%), including 1,602 females, had a normal qualitative test with no quantitative result. This low percentage should continue to decrease since quantitative testing is standard protocol for all new recruits at U.S. Air Force basic military training as well as new officer accessions at the U.S. Air Force Academy and Officer Training School (email communication, Maj Dianne Frankel and Lt Col Kevin Baldovich, Dec. 2019 and Jan. 2020, respectively).

While the article by Lee and Poitras provides valuable information, G6PD deficiency surveillance in the tafenoquine era should incorporate quantitative values. These values should also be documented in service members’ deployment readiness records. For example, the Aeromedical Services Information Management System, the U.S. Air Force’s readiness platform, defines G6PD status as either “normal” or “deficient”—essentially as a qualitative test, even if a quantitative enzyme activity level is available in the electronic health record. This may lead to improper prescription of tafenoquine to airmen, particularly females, who are coded as having “normal” G6PD activity levels but whose levels are in fact intermediate.

Author affiliations: Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD (Maj Sayers; Lt Col Webber); Public Health and Preventive Medicine Department, U.S. Air Force School of Aerospace Medicine, Wright-Patterson Air Force Base, OH (Lt Col Webber).

Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Air Force, the Department of Defense, or the U.S. Government.

References

  1. Lee J, Poitras BT. Prevalence of glucose-6-phosphate dehydrogenase deficiency, U.S. Armed Forces, May 2004–Sept. 2018. MSMR. 2019;26(12):14–17.
  2. Haston JC, Hwang J, Tan KR. Guidance for using tafenoquine for prevention and antirelapse therapy for malaria—United States, 2019. MMWR Morb Mortal Wkly Rep. 2019;68(46):1062–1068.
  3. Commons RJ, McCarthy JS, Price RN. Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency. Med J Aust. 2020;212(4):152–153.e1.
  4. Price RN, Commons RJ, Battle KE, Thriemer K, Mendis K. Plasmodium vivax in the era of the shrinking P. falciparum map. Trends Parasitol. 2020;36(6):560–570.
  5. Defense Health Agency, Department of Defense. Procedural Instruction 6025.14. Active Duty Service Members (ADSM) Erythrocyte Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency and Sickle Cell Trait (SCT) Screening. 6 Dec. 2018.

In reply:

We appreciate the response by Drs. Sayers and Webber to our article published in the Dec. 2019 issue of the MSMR on the prevalence of G6PD deficiency among active duty service members. We are in agreement that quantitative as well as qualitative testing for the genetic condition is imperative to prevent the potentially harmful side effects from the use of the 8-aminoquinoline (8-AQ) class of antimalarial drugs (tafenoquine and primaquine) for malaria chemoprophylaxis and radical cure. We applaud the Air Force for the implementation of quantitative screening of G6PD deficiency among new recruits.

Our article highlights the need for leadership awareness of G6PD deficiency diagnoses to reduce the possibility of adverse events from the use of the 8-AQ class of antimalarial drugs. The inclusion of quantitative G6PD testing is an important tool to further identify at-risk service members.

Respectfully,

MAJ Jangwoo Lee, PhD; Beth Poitras, MPH

You also may be interested in...

Incidence and Management of Chronic Insomnia, Active Component, U.S. Armed Forces, 2012 to 2021

Article
1/1/2023
Incidence and Management of Chronic Insomnia, Active Component, U.S. Armed Forces, 2012 to 2021

Incidence and Management of Chronic Insomnia, Active Component, U.S. Armed Forces, 2012 to 2021.

Recommended Content:

Health Readiness & Combat Support | Public Health | Medical Surveillance Monthly Report

Increased Prevalence of Overweight and Obesity and Incidence of Prediabetes and Type 2 Diabetes During the COVID-19 Pandemic, Active Component Service Members, U.S. Armed Forces, 2018 to 2021

Article
1/1/2023
Trends in the incidence of eating disorders among active component service members, 2017 to 2021.

Increased Prevalence of Overweight and Obesity and Incidence of Prediabetes and Type 2 Diabetes During the COVID-19 Pandemic, Active Component Service Members, U.S. Armed Forces, 2018 to 2021.

Recommended Content:

Health Readiness & Combat Support | Public Health | Medical Surveillance Monthly Report

Trends in the Incidence of Eating Disorders Among Active Component Service Members, 2017 to 2021

Article
1/1/2023
Changes in the prevalence of overweight and obesity and in the incidence of prediabetes and type 2 diabetes during the COVID-19 pandemic, active component service members, U.S. Armed Forces, 2018 to 2021.

Trends in the Incidence of Eating Disorders Among Active Component Service Members, 2017 to 2021.

Recommended Content:

Health Readiness & Combat Support | Public Health | Medical Surveillance Monthly Report

Seroepidemiologic Investigation of a COVID-19 Outbreak Aboard a U.S. Navy Ship

Article
12/1/2022
Cover 1

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus, the cause of coronavirus disease 2019 (COVID-19), has been responsible for the largest respiratory illness pandemic since the influenza pandemic of 1918.

Recommended Content:

Medical Surveillance Monthly Report

Emergency Mental Health Care Utilization and the COVID-19 Pandemic Among U.S. Armed Forces and Dependents, 1 January 2017 to 31 March 2021

Article
12/1/2022
Cover 3

The COVID-19 pandemic brought with it concerns for the effects on mental health, from both the disease itself and the steps taken to combat it.

Recommended Content:

Medical Surveillance Monthly Report

Brief Review: Clinical and Epidemiologic Characteristics of Genital Skin Lesions Due to Infectious Causes

Article
12/1/2022
Brief Review: Clinical and Epidemiologic Characteristics of Genital Skin Lesions Due to Infectious Causes

During the current global mpox outbreak, many cases have presented atypically with skin lesions localized to the genital and perianal areas.

Recommended Content:

Medical Surveillance Monthly Report

Brief Report: Pediatric Vaccine Completion and Compliance Among Infants Born to Female Active Duty Service Members, 2006–2016

Article
11/1/2022
4

Rotavirus gastroenteritis is the leading cause of diarrhea-associated morbidity and mortality among children under age 5 worldwide.

Recommended Content:

Medical Surveillance Monthly Report

Update: Cold Injuries, Active and Reserve Components, U.S. Armed Forces, July 2017–June 2022

Article
11/1/2022
1

Cold injuries are of significant military concern because of their adverse impact on operations and the high financial costs of treatment and disability.

Recommended Content:

Medical Surveillance Monthly Report

In-Theater Mental Health Disorders Among U.S. Soldiers Deployed Between 2008 and 2013

Article
11/1/2022
3

Mental health is a significant concern within the U.S. military, and service members are at substantial risk for developing an array of mental health conditions including anxiety, depression, stress/adjustment issues, and sleep-related disorders.

Recommended Content:

Medical Surveillance Monthly Report

Update: Contraception Among Active Component Service Women, U.S. Armed Forces, 2017–2021

Article
10/1/2022
2

This report summarizes the annual prevalence of permanent sterilization, as well as use of long- and short-acting reversible contraceptives (LARCs and SARCs, respectively), contraceptive counseling services, and use of emergency contraceptives from 2017 through 2021 among active component U.S. service women.

Recommended Content:

Medical Surveillance Monthly Report

Viral hepatitis C, active component, U.S. Armed Forces, 2011–2020

Article
10/1/2022
1

This study reports updated numbers and incidence rates of hepatitis C virus (HCV) infection among active component members of the U.S. military using a revised case definition during a 10-year surveillance period between 2011 and 2020.

Recommended Content:

Medical Surveillance Monthly Report

Surveillance Snapshot: Influenza Immunization Among U.S. Armed Forces Healthcare Workers, August 2017–April 2022

Article
10/1/2022
3

Immunization Among U.S. Armed Forces Healthcare Workers

Recommended Content:

Medical Surveillance Monthly Report

Letter to the Editor: Clarification of Hepatitis C Virus Screening with Case Definitions and Prevalence Among Trainees

Article
9/1/2022
Cover 3

We read with interest the brief report regarding the prevalence of Hepatitis C Virus (HCV) infection in basic military trainee blood donors by Kasper and colleagues in the November 2021 issue of the Medical Surveillance Monthly Report (MSMR),1 an update of a previous similar report

Recommended Content:

Medical Surveillance Monthly Report

Update: Routine Screening for Antibodies to Human Immunodeficiency Virus, U.S. Armed Forces, Active and Reserve Components, January 2017–June 2022

Article
9/1/2022
Cover 1

This report provides an update through June 2022 of routine screening results for antibodies to the human immunodeficiency virus (HIV) among members of the active and reserve components of the U.S. Armed Forces. During the full 5 and 1/2-year surveillance period, the HIV seropositivity rates for active component service members were 0.21 positives per 1,000 members of the Army, 0.24 for the Navy, 0.16 for the Marine Corps, and 0.14 for the Air Force.

Recommended Content:

Medical Surveillance Monthly Report

Evaluation of the MSMR Surveillance Case Definition for Incident Cases of Hepatitis C

Article
9/1/2022
Cover 2

The validity of military hepatitis C virus (HCV) surveillance data is uncertain due to the potential for misclassification introduced when using administrative databases for surveillance purposes. The objectives of this study were to assess the validity of the surveillance case definition used by the Medical Surveillance Monthly Report (MSMR) for HCV, the over and underestimation of cases from surveillance data, and the true burden of HCV disease in the U.S. military.

Recommended Content:

Medical Surveillance Monthly Report
<< < 1 2 3 4 5  ... > >> 
Showing results 1 - 15 Page 1 of 14
Refine your search
Last Updated: October 24, 2022
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on Twitter Follow us on YouTube Sign up on GovDelivery